RADPLAT for maxillary sinus cancer

Phase 2

• Conditions: maxillary sinus cancer, head and neck cancer; maxillary sinus cancer; D008444

• Registration Number: JPRN-jRCTs031180425
• Lead Sponsor: Tanaka Norimitsu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

1.Maxillary sinus cancer pathologically proved as squamous cell carcinoma
2.Maxillary sinus cancer staged as T3 and T4 on UICC, 2009.
3.No metastatic lymph node
4.Primary treatment case
5.Measurable disease
6.Cather accessible case into the feeding arteries, including internal maxillary artery, facial artery and transverse facial artery.
7.Pursuing of non-surgical and organ-preserving treatment, but salvage surgery for residual cancer can be done.
8.Age of the patient: >=20 y.o. and <=75 y.o.
9.Prognosis better than 8 months
10. ECOG Performance status (PS) 0 or 1

Exclusion Criteria

1)Bone suppression state
2)Severe infection in the head and neck region
3)Severe systemic complication, such as intestinal paralysis, ileus, interstitial pneumonitis, pulmonary fibrosis, uncontrolled DM, heart failure, renal failure, and liver failure.
4)Synchronized active cancer
5)History of irradiation for head and neck region
6)History of allergy for cisplatin or contrast medium
7)Severe mental disorder
8)Pregnant, unwell to practice contraception during the study or lactating female
9)Preoperative therapy for planed surgery
10)Inaccessible catheterization due to arteriosclerosis
11)Other causes judged unpreferable by attending physician for this protocol treatment

Study & Design

• Study Type: Interventional
• Study Design: Not specified